Amarin Corp Plc (AMRN)

[AVII77]

I agree. The LDL-c hypothesis is questionable.

But two wrongs don't make a right.

If we want to say that the FDA should have approved V based on ANCHOR's trig reduction, then we must be ready to agree they should have approved Evacetrapib based on its lipid effects too. (And of course, ACCELERATE shows that would have been a mistake)